News

04. January 2021

Geistlich Pharma will have a new CEO from July 2021

In January 2021, Ralf P. Halbach has taken up the position as designated CEO at Geistlich Pharma. As of July 1, 2021, he will officially take over from Paul Note, who has reached retirement age. A smooth handover will take place until then.

Geistlich Pharma is pleased to welcome Ralf P. Halbach as designated CEO as per January 1st. He will take over the position of CEO in the middle of the year from Paul Note, who has led the company with a steady hand for the past 16 years and now has reached retirement age. Geistlich Pharma has enjoyed consistent growth and numerous successes during his time in charge.

Ralf P. Halbach has had a long career as a global Senior Healthcare Executive with more than 25 years of international experience in the pharmaceutical and diagnostic sector. Over the last ten years, Ralf P. Halbach has worked for Roche in a range of different functions, divisions, and regions. He has held positions in global strategic marketing (USA), supporting the largest oncology brand, as well as regional commercial functions in north-west Africa, south-east Asia and Central Europe. Prior to this, he worked as General Manager for two pharma start-ups. Ralf P. Halbach was born and grew up in Barcelona (Spain) and holds dual Swiss-German citizenship. He holds a PhD in Organic Chemistry from the University of Basel (Switzerland) and an MBA from INSEAD (France). Ralf P. Halbach has moved with his wife and three children to Switzerland from Poland, where they lived until recently.

We thank Paul Note for his years of valuable commitment to the growth and success of Geistlich Pharma and look forward to continuing to count on his experienced leadership until the middle of 2021. We congratulate Ralf P. Halbach on his appointment to this position and wish him a good start in the Geistlich family.